Teleflex Incorporated

A multinational prospective cohort study of over 6,670 ICU patients across eight countries demonstrated a 70.5% reduction in central line-associated bloodstream infections (CLABSIs) with chlorhexidine-impregnated catheters compared to plain catheters.

A new retrospective study published in Obesity Surgery demonstrates that Teleflex's Titan SGS™ Stapler significantly reduces post-operative GERD rates following sleeve gastrectomy compared to traditional multi-fire staplers.

Teleflex's QuikClot Control+ Hemostatic Device received FDA 510(k) clearance for expanded use in all grades of internal and external bleeding, significantly broadening its clinical applications beyond severe bleeding scenarios.

New clinical data presented at the 2025 AUA Annual Meeting shows the UroLift System provides better early patient satisfaction and faster symptom relief compared to Rezūm and tamsulosin for BPH treatment.

• The CLEAR SYNERGY (OASIS-9) trial found that spironolactone did not significantly improve composite outcomes in patients post-MI who underwent PCI compared to placebo. • An on-treatment analysis suggested potential benefits with spironolactone, but high drug discontinuation rates complicate interpretation of these findings. • Spironolactone was associated with a reduced risk of new or worsening heart failure in both intention-to-treat and on-treatment analyses. • The study highlights the challenge of demonstrating additional benefits with new therapies in a patient population already receiving optimal post-MI treatment.